CY1108294T1 - Πρωτεϊνες καρκινικων δεικτων και οι χρησεις τους - Google Patents
Πρωτεϊνες καρκινικων δεικτων και οι χρησεις τουςInfo
- Publication number
- CY1108294T1 CY1108294T1 CY20081100911T CY081100911T CY1108294T1 CY 1108294 T1 CY1108294 T1 CY 1108294T1 CY 20081100911 T CY20081100911 T CY 20081100911T CY 081100911 T CY081100911 T CY 081100911T CY 1108294 T1 CY1108294 T1 CY 1108294T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- tumour
- fluids
- marker proteins
- preparation
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Η εφεύρεση αναφέρεται στις πρωτεΐνες των καρκινικών δεικτών και στην παρασκευή τους από υγρά ενός ή περισσότερων ασθενών με καρκίνο, όπου τα υγρά που αναφέρθηκαν είναι εκείνα τα οποία συλλέγονται σε μια σωματική κοιλότητα ή χώρο, ο οποίος υπάρχει φυσιολογικά ή είναι αποτέλεσμα της ύπαρξης καρκίνου ή κάποιας ιατρικής παρέμβασης στον καρκίνο. Η εφεύρεση αναφέρεται επίσης στην παρασκευή πρωτεϊνών καρκινικών δεικτών από τις εκκρίσεις των ασθενών με καρκίνο. Οι πρωτεΐνες των καρκινικών δεικτών μπορούν να χρησιμοποιηθούν ως αντιδραστήρια ανοσολογικών προσδιορισμών αναφορικά με την ανίχνευση των δεικτών των αυτοαντισωμάτων που σχετίζονται με την ύπαρξη καρκίνου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0226622A GB2395270B (en) | 2002-11-14 | 2002-11-14 | Tumour marker proteins and uses thereof |
EP03773863A EP1563307B1 (en) | 2002-11-14 | 2003-11-13 | Tumour marker proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108294T1 true CY1108294T1 (el) | 2014-02-12 |
Family
ID=9947849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100911T CY1108294T1 (el) | 2002-11-14 | 2008-08-25 | Πρωτεϊνες καρκινικων δεικτων και οι χρησεις τους |
Country Status (14)
Country | Link |
---|---|
US (2) | US8592169B2 (el) |
EP (2) | EP1563307B1 (el) |
JP (1) | JP4759267B2 (el) |
AT (1) | ATE397217T1 (el) |
AU (1) | AU2003282245B2 (el) |
CA (1) | CA2545930C (el) |
CY (1) | CY1108294T1 (el) |
DE (1) | DE60321375D1 (el) |
DK (1) | DK1563307T3 (el) |
ES (1) | ES2305530T3 (el) |
GB (3) | GB2424070B (el) |
PT (1) | PT1563307E (el) |
SI (1) | SI1563307T1 (el) |
WO (1) | WO2004044590A1 (el) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9810040D0 (en) | 1998-05-11 | 1998-07-08 | Univ Nottingham | Blood borne tumour markers |
GB9827228D0 (en) * | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
US20030232399A1 (en) * | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
GB2424070B (en) | 2002-11-14 | 2007-06-27 | Univ Nottingham | Methods for preparing tumour marker proteins |
US7858323B2 (en) | 2004-06-09 | 2010-12-28 | The Regents Of The University Of Michigan | Phage microarray profiling of the humoral response to disease |
JP2006242869A (ja) * | 2005-03-04 | 2006-09-14 | Kyushu Univ | 腫瘍マーカーとしての抗nasp抗体及び抗tmf抗体 |
SI1889059T1 (sl) | 2005-05-27 | 2009-12-31 | Oncimmune Ltd | Izboljšani imunotestni postopek |
GB2426581A (en) * | 2005-05-27 | 2006-11-29 | Univ Nottingham | Immunoassay methods |
WO2006132587A1 (en) * | 2005-06-10 | 2006-12-14 | Forskarpatent I Syd Ab | Tumour marker in brca2 associated breast cancer |
JP5211315B2 (ja) * | 2006-07-25 | 2013-06-12 | 国立大学法人愛媛大学 | 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法 |
WO2008032084A1 (en) * | 2006-09-13 | 2008-03-20 | Oncimmune Ltd | Improved immunoassay methods |
CN101632020B (zh) | 2006-09-13 | 2013-11-27 | 昂西免疫有限公司 | 改进的免疫测定方法 |
GB2441824A (en) * | 2006-09-13 | 2008-03-19 | Oncimmune Ltd | Immunoassay method |
WO2008103815A2 (en) * | 2007-02-23 | 2008-08-28 | Predictive Biosciences Corporation | Clinical intervention directed diagnostic methods |
BRPI0810176A2 (pt) * | 2007-04-12 | 2014-12-30 | Proteosys Ag | Regulação autoimune de câncer de próstata ppor anexina a3 |
GB0725239D0 (en) * | 2007-12-24 | 2008-02-06 | Oncimmune Ltd | Calibrator for autoantibody assay |
JP5907732B2 (ja) * | 2009-01-14 | 2016-04-26 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 比に基づく生体マーカーおよびそれを使用する方法 |
WO2011116209A2 (en) | 2010-03-17 | 2011-09-22 | The Regents Of The University Of Michigan | Using phage epitopes to profile the immune response |
CA3002192C (en) | 2010-03-26 | 2023-03-07 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
US20130040839A1 (en) * | 2011-06-27 | 2013-02-14 | Ambergen, Inc. | Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery |
TW201312117A (zh) * | 2011-07-28 | 2013-03-16 | Univ Pennsylvania | 用以診斷與漿液相關之腫瘤細胞的症狀及特性的方法及試劑 |
CA2959408A1 (en) * | 2014-09-04 | 2016-03-10 | Provista Diagnostics, Inc. | Biomarkers for detection of breast cancer |
SG11201707538XA (en) | 2015-03-17 | 2017-10-30 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
CN113848322A (zh) * | 2015-12-11 | 2021-12-28 | 善福德健康 | 用于监测乳腺癌治疗的试剂和方法 |
GB2600701A (en) | 2020-11-04 | 2022-05-11 | Oncimmune Ltd | Antibody assay |
EP4182693A2 (en) | 2020-07-14 | 2023-05-24 | Oncimmune Limited | Use of antigen combination for detecting autoantibodies in lung cancer |
CN113721021B (zh) * | 2021-09-16 | 2023-07-07 | 郑州大学 | Prkcz自身抗体在食管鳞癌辅助诊断中的应用 |
GB2622246A (en) | 2022-09-08 | 2024-03-13 | Oncimmune Germany Gmbh | Antibody assay |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ211453A (en) * | 1984-03-22 | 1989-01-06 | Biotechnology Research Enterpr | Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides |
ATE77700T1 (de) | 1986-03-10 | 1992-07-15 | Imre Corp | Immunkomplextestverfahren. |
WO1989001153A1 (en) | 1987-07-24 | 1989-02-09 | Xoma Corporation | Methods for breast cancer detection |
US4937185A (en) * | 1987-07-31 | 1990-06-26 | The Ohio State University Research Foundation | Detection of circulating antibodies to a cancer marker protein |
US5241052A (en) * | 1988-03-04 | 1993-08-31 | New England Deaconess Hospital Corporation | Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses |
US7282345B1 (en) * | 1989-08-04 | 2007-10-16 | Schering Ag | C-erbB-2 external domain: GP75 |
DK0498851T3 (da) * | 1989-11-03 | 1996-05-13 | Donald L Morton | Tumorassocieret urinantigen, anvendelse af antigene underenheder og fremgangsmåder til detektion |
US5157020A (en) * | 1990-05-24 | 1992-10-20 | Research Corporation Tech., Inc. | Synthetic senescent cell antigen |
DK9091D0 (da) | 1991-01-18 | 1991-01-18 | Novo Nordisk As | Fremgangsmaade til fremstilling af antistoffer |
DE4120412C1 (el) * | 1991-06-20 | 1993-01-07 | Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De | |
US6322989B1 (en) * | 1991-11-25 | 2001-11-27 | Yoreh Biotechnologies, Ltd. | Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit |
US6280962B1 (en) * | 1991-11-25 | 2001-08-28 | Yoreh Biotechnologies Ltd. | Whole blood/mitogen assay for the early detection of a subject with cancer and kit |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5753522A (en) * | 1991-12-06 | 1998-05-19 | Legacy Good Samaritan Hospital And Medical Center | Purified protein for identifying a cancer-associated retinopathy autoantibody |
WO1993021529A1 (en) | 1992-04-14 | 1993-10-28 | Duke University | Method of detecting tumors containing complexes of p53 and hsp70 |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5763164A (en) | 1993-04-16 | 1998-06-09 | Northwestern University | Immunogenic cancer proteins and peptides and methods of use |
US5747268A (en) * | 1993-04-22 | 1998-05-05 | Dade International Inc. | Tumor marker control |
US5744144A (en) * | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
US5721105A (en) * | 1994-02-20 | 1998-02-24 | B.R.A.H.M.S. Diagnostica Gmbh | Method for the immunological determination of proteins and kit for carrying out the method |
JPH07294530A (ja) | 1994-04-20 | 1995-11-10 | Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk | 病原体に対する体液中の抗体検出法 |
CA2148971A1 (en) | 1994-05-26 | 1995-11-27 | Izak Bahar | Calibrator matrix |
JPH10505819A (ja) | 1994-06-24 | 1998-06-09 | ヴラディミール ピー. トーチリン | 腫瘍の治療及び予防のための自己抗体の使用方法 |
IL110464A0 (en) | 1994-07-26 | 1994-10-21 | Univ Ramot | Novel proteins for the diagnosis, imaging, and therapy of human cancer |
US5561049A (en) * | 1994-09-21 | 1996-10-01 | Behringwerke Ag | Method for detecting antibodies |
US5876728A (en) * | 1995-02-15 | 1999-03-02 | Howard David Kass | Natural composition extracted from plants used in the treatment of cancer |
AUPN568095A0 (en) | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
GB9521544D0 (en) | 1995-10-20 | 1995-12-20 | Univ Dundee | Activation of P53 protein and therapeutic applications thereof |
JPH09189702A (ja) | 1996-01-09 | 1997-07-22 | Hitachi Chem Co Ltd | 抗ムチン抗体の測定法、癌の測定法及び癌診断薬 |
AU3889997A (en) * | 1996-08-16 | 1998-03-06 | Johns Hopkins University School Of Medicine, The | Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same |
US8021666B2 (en) * | 1997-02-18 | 2011-09-20 | Sloan-Kettering Institute For Cancer Research | Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen |
EP1019727A1 (en) | 1997-06-03 | 2000-07-19 | Amdl, Inc | Immunoassay for the detection of cancer |
ATE266203T1 (de) * | 1997-06-26 | 2004-05-15 | Univ Michigan | Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum |
DE19805815C1 (de) * | 1998-02-13 | 1999-11-11 | Ansgar W Lohse | Diagnostikum zum Erkennen der autoimmunen Hepatitis |
JP4083855B2 (ja) | 1998-02-16 | 2008-04-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肺癌予後検査方法 |
GB9810040D0 (en) | 1998-05-11 | 1998-07-08 | Univ Nottingham | Blood borne tumour markers |
AUPP349098A0 (en) | 1998-05-13 | 1998-06-04 | South Eastern Sydney Area Health Service | A method of monitoring pancreatic tissue viability |
GB9821170D0 (en) * | 1998-09-30 | 1998-11-25 | Univ Ulster | Marker |
EP1125133A1 (en) * | 1998-11-03 | 2001-08-22 | Cell Genesys, Inc. | Novel cancer-associated antigens and methods of their identification |
WO2000026668A2 (en) * | 1998-11-05 | 2000-05-11 | The Regents Of The University Of Michigan | S100 proteins and autoantibodies as serum markers for cancer |
US6387639B1 (en) * | 1998-11-10 | 2002-05-14 | Sloan-Kettering Institute For Cancer Research | Ma family polypeptides and anti-Ma antibodies |
GB9827228D0 (en) * | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
JP2000281255A (ja) * | 1999-03-31 | 2000-10-10 | Seiko Epson Corp | 記録装置 |
US7807810B2 (en) * | 1999-04-08 | 2010-10-05 | The Ohio State University Research Foundation | Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby |
US6645465B2 (en) * | 1999-08-06 | 2003-11-11 | Michigan, University Of The Regents | Annexin proteins and autoantibodies as serum markers for cancer |
US20020064801A1 (en) * | 1999-12-01 | 2002-05-30 | Ryan Jeffrey R. | Novel and practical serological assay for the clinical diagnosis of leishmaniasis |
US6667160B2 (en) * | 2000-03-15 | 2003-12-23 | Kenneth D. Fine | Method for diagnosing immunologic food sensitivity |
US20030138860A1 (en) * | 2000-06-14 | 2003-07-24 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
US20030232399A1 (en) * | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
US6379550B1 (en) * | 2000-07-24 | 2002-04-30 | Health Research, Inc. | Method for detecting PSA and its molecular forms using thiophilic gel |
EP1354206A2 (en) | 2000-12-13 | 2003-10-22 | Bio-Rad Laboratories, Inc. | Standard diluent for multiplex assays |
CA2451045A1 (en) * | 2001-06-21 | 2003-09-04 | New York University | Mycobacterial proteins as early antigens for serodiagnosis and vaccines |
US20030199464A1 (en) * | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
US20030049692A1 (en) * | 2002-09-16 | 2003-03-13 | Norman Latov | Detection of anti-glycolipid antibodies by latex agglutination assay |
GB2424070B (en) | 2002-11-14 | 2007-06-27 | Univ Nottingham | Methods for preparing tumour marker proteins |
JP2005352771A (ja) * | 2004-06-10 | 2005-12-22 | Hitachi Software Eng Co Ltd | 発現プロファイルによるパターン認識システム |
US20060141547A1 (en) * | 2004-11-16 | 2006-06-29 | Das Hasi R | Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis |
GB2426581A (en) | 2005-05-27 | 2006-11-29 | Univ Nottingham | Immunoassay methods |
EP1789435B1 (en) | 2005-09-12 | 2010-02-24 | Industry Foundation of Chonnam National University | A method for production of mature natural killer cell |
TWI304443B (en) | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
WO2008032084A1 (en) | 2006-09-13 | 2008-03-20 | Oncimmune Ltd | Improved immunoassay methods |
CN101632020B (zh) * | 2006-09-13 | 2013-11-27 | 昂西免疫有限公司 | 改进的免疫测定方法 |
GB0725239D0 (en) * | 2007-12-24 | 2008-02-06 | Oncimmune Ltd | Calibrator for autoantibody assay |
-
2002
- 2002-11-14 GB GB0604694A patent/GB2424070B/en not_active Expired - Fee Related
- 2002-11-14 GB GB0604693A patent/GB2424273B/en not_active Expired - Fee Related
- 2002-11-14 GB GB0226622A patent/GB2395270B/en not_active Expired - Fee Related
-
2003
- 2003-11-13 US US10/534,773 patent/US8592169B2/en not_active Expired - Lifetime
- 2003-11-13 AU AU2003282245A patent/AU2003282245B2/en not_active Ceased
- 2003-11-13 DE DE60321375T patent/DE60321375D1/de not_active Expired - Lifetime
- 2003-11-13 JP JP2004550841A patent/JP4759267B2/ja not_active Expired - Fee Related
- 2003-11-13 SI SI200331307T patent/SI1563307T1/sl unknown
- 2003-11-13 EP EP03773863A patent/EP1563307B1/en not_active Expired - Lifetime
- 2003-11-13 WO PCT/GB2003/004950 patent/WO2004044590A1/en active IP Right Grant
- 2003-11-13 EP EP08007680A patent/EP1967856A3/en not_active Withdrawn
- 2003-11-13 PT PT03773863T patent/PT1563307E/pt unknown
- 2003-11-13 ES ES03773863T patent/ES2305530T3/es not_active Expired - Lifetime
- 2003-11-13 CA CA2545930A patent/CA2545930C/en not_active Expired - Fee Related
- 2003-11-13 AT AT03773863T patent/ATE397217T1/de active
- 2003-11-13 DK DK03773863T patent/DK1563307T3/da active
-
2008
- 2008-08-25 CY CY20081100911T patent/CY1108294T1/el unknown
-
2013
- 2013-11-19 US US14/083,874 patent/US20140080736A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1967856A3 (en) | 2009-04-15 |
ES2305530T3 (es) | 2008-11-01 |
EP1563307A1 (en) | 2005-08-17 |
GB0604694D0 (en) | 2006-04-19 |
PT1563307E (pt) | 2008-07-16 |
EP1967856A2 (en) | 2008-09-10 |
AU2003282245A1 (en) | 2004-06-03 |
EP1563307B1 (en) | 2008-05-28 |
US20060094069A1 (en) | 2006-05-04 |
JP4759267B2 (ja) | 2011-08-31 |
GB2424070B (en) | 2007-06-27 |
DE60321375D1 (de) | 2008-07-10 |
ATE397217T1 (de) | 2008-06-15 |
WO2004044590A1 (en) | 2004-05-27 |
GB0604693D0 (en) | 2006-04-19 |
US20140080736A1 (en) | 2014-03-20 |
SI1563307T1 (sl) | 2008-10-31 |
GB2424273B (en) | 2007-06-27 |
CA2545930A1 (en) | 2004-05-27 |
AU2003282245B2 (en) | 2010-05-20 |
JP2006506612A (ja) | 2006-02-23 |
GB0226622D0 (en) | 2002-12-24 |
GB2395270A (en) | 2004-05-19 |
CA2545930C (en) | 2016-07-12 |
DK1563307T3 (da) | 2008-09-29 |
GB2424273A (en) | 2006-09-20 |
GB2395270B (en) | 2006-08-16 |
US8592169B2 (en) | 2013-11-26 |
GB2424070A (en) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108294T1 (el) | Πρωτεϊνες καρκινικων δεικτων και οι χρησεις τους | |
DE602006018578D1 (de) | Diagnose- und prognoseverfahren von blasenkrebs. | |
CY1105129T1 (el) | Οπτικος αισθητηρας για την επι τοπου μετρηση αναλυομενων ουσιων | |
CY1115366T1 (el) | Δεικτες ογκου | |
DE69930666D1 (de) | Krebsnachweisverfahren und reagenzien | |
DE602006007703D1 (de) | Verbesserte immuntestverfahren | |
ATE529161T1 (de) | Tumorbehandlungs-identifikationssystem | |
ATE400813T1 (de) | Tumormarker für frühes krebsstadium | |
CY1109684T1 (el) | Συστημα δοκιμης αναλυτη για τον προσδιορισμο της συγκεντρωσης ενος αναλυτη σε ενα φυσιολογικο ή υδατικο ρευστο | |
CY1105923T1 (el) | Οπτικος αισθητηρας για επι τοπου μετρηση αναλυτων | |
DE60312737D1 (de) | Verfahren und vorrichtung für messungen im blut | |
FI20050501L (fi) | Etätunnistinjärjestelmä ja -menetelmä sekä etätunnistimen käyttö | |
DK1853735T3 (da) | Fremgangsmåder til detektering af progressionen af cervikal dysplasi i let grad | |
ATE555385T1 (de) | N1,n12-diacetylspermin als tumormarker | |
DE602004012031D1 (de) | Detektionseinheit zur Röntgenstreumessung | |
DE602004017317D1 (de) | Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome | |
SE0702207L (sv) | Förfarande vid och en anordning för opåverkad materialundersökning | |
ATE303451T1 (de) | Nanopartikeln für optische sensoren | |
DE502004005003D1 (de) | Aufklärungssystem zur Ermittlung von Zielen und Zielbewegungen | |
CY1117148T1 (el) | Βελτιωμενες μεθοδοι ανοσοπροσδιορισμου | |
DE602004015896D1 (de) | Kurvenlichtsystem enthaltend eine Steuervorrichtung und autonome Kurvenerkennungsmittel | |
IT1248782B (it) | Miglioramenti relativi al sistema di guida di un utensile lungo un percorso sotterraneo | |
UA3761U (uk) | Спосіб порівняльної оцінки ефективності лікування | |
DE602006015957D1 (de) | Quantitative assays für ras p21 in körperflüssigkeiten |